MARKSANS PHARMA
|
The Current P/E Ratio of MARKSANS PHARMA is 27.20.
| Share Price | ₹252.2 | Jun 12,2026 |
| Market Cap | ₹11,427.4 Cr | |
| Earnings-TTM | ₹420.1 Cr | TTM-Consolidated Results |
| Price/Earnings | 27.20x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of MARKSANS PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹11,427.4 Cr] as on Jun 12,2026
(/) Earnings [ ₹420.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 27.20x ]
Thus, for MARKSANS PHARMA , the investors are currently willing to pay 27.20 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of MARKSANS PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of MARKSANS PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of MARKSANS PHARMA
PE Ratio Performance Analysis for MARKSANS PHARMA
- MARKSANS PHARMA 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 15.83x.
- MARKSANS PHARMA 's operated at median p/e ratio of 11.99x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, MARKSANS PHARMA 's p/e ratio peaked in Mar2025 at 26.48x.
- MARKSANS PHARMA 's p/e ratio hit its five-year low in Mar2021 of 8.67x.
How does MARKSANS PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| MARKSANS PHARMA | 420.06 | 27.20 | 11,427.4 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,564.50 | 37.50 | 433,620.0 |
| DIVIS LABORATORIES LTD | 2,568.00 | 68.57 | 176,087.0 |
| TORRENT PHARMACEUTICALS LTD | 2,138.00 | 72.42 | 154,837.0 |
| CIPLA LTD | 3,869.79 | 28.99 | 112,194.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 25.66 | 106,328.0 |
| MANKIND PHARMA LTD | 1,926.41 | 51.01 | 98,270.3 |
| LUPIN LTD | 5,355.47 | 19.57 | 104,830.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 22.11 | 111,123.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 24.19 | 84,710.0 |
| LAURUS LABS LTD | 889.85 | 84.64 | 75,316.2 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs MARKSANS PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 19.57x |
| Max industry PE | 84.64x |
| Median industry PE | 28.99x |
| Average industry PE | 41.99x |
You may also like the below Video Courses